LDL Cholesterol: What Your Number Means & How to Lower It

LDL tools and updated resources

Explore the LDL reduction calculator for dose-specific statin estimates and combination scenarios. These tools support education and a discussion with your clinician; they do not select treatment.

What to read next

• Start here for the cholesterol domain: LDL Cholesterol: What the Number Means and Why It Matters.
• Compare the risk markers: Cholesterol Blood Tests: LDL-C vs ApoB vs Lp(a) vs hs-CRP.
• Build the nutrition foundation: Eating Well Without Overthinking It.
• Read the evidence base: The Science Behind Vital8.
• Review the scoring appendix: Vital8 Methods and Scoring System.
• Use the tool: Vital8 Score.

What LDL is, in plain terms

LDL cholesterol, often called "bad cholesterol," is a fatty particle that circulates in your blood. When too much of it builds up over years, it gets trapped in the walls of your arteries and forms plaque, the process behind most heart attacks, strokes, and poor circulation in the legs.[1][2] A lower LDL, kept low over a lifetime, is one of the most reliable ways to prevent these events.[1][2]

This article explains where that number comes from, what a good level is, and how to lower it with lifestyle and, when needed, medication.

The one number that quietly shapes a lifetime

Heart disease is the single leading cause of death in the United States, and atherosclerotic disease, the artery-clogging process LDL drives, is the leading cause of death worldwide.[3][4] Much of that toll is preventable. We now understand LDL so well, and can lower it so safely, that a great deal of this disease can be pushed off for decades or avoided altogether, letting people enjoy many more healthy years.[1][2]

This is why cholesterol is one of the American Heart Association's Life's Essential 8, the short list of health behaviors and measurements that most determine cardiovascular health: diet, physical activity, avoiding nicotine, healthy sleep, healthy weight, and healthy levels of blood sugar, blood pressure, and blood lipids. LDL is the lipid that matters most, and it is the number behind the cholesterol domain of your Vital8 score.

Cholesterol: essential in every cell, dangerous in the bloodstream

Cholesterol itself is not the villain. It is a vital building block of life. Every cell in the human body contains cholesterol in its outer membrane, and nearly every cell can manufacture its own.[5] Cholesterol is the raw material for hormones, vitamin D, and the bile that digests food. Life is impossible without it.

The problem is not cholesterol inside cells. It is cholesterol traveling in the blood. Because cholesterol does not dissolve in water, it must be ferried through the bloodstream inside particles wrapped in a protein called apolipoprotein B, or apoB. LDL is the most abundant of these apoB particles.[6] When too many of them circulate, they slip into the wall of an artery and get trapped there.[6]

That trapped, apoB-containing cholesterol is what starts a plaque. The body treats it as an injury: immune cells rush in, swallow the cholesterol, turn into foam cells, and die, leaving behind a growing, inflamed, fatty deposit. Scientists call this the response-to-retention model. Atherosclerosis is fundamentally a disease of apoB particles being retained in artery walls over time.[6]

So the danger is not that cells make cholesterol. It is that the body cannot clear enough of it out of circulation.[5] That single insight, clearance rather than production, is what makes LDL both understandable and treatable. It explains why every effective therapy works by helping the body remove LDL from the blood faster.[7]

Where the science came from: families, receptors, and a Nobel Prize

The modern story of cholesterol began not in a pharmacy but in families. More than a century ago, doctors noticed that some families had cholesterol deposits in their skin and tendons and suffered heart attacks at strikingly young ages, sometimes in their 30s and 40s, sometimes even in childhood. This inherited condition is called familial hypercholesterolemia, or FH.[8][9]

In the 1970s and early 1980s, Michael Brown and Joseph Goldstein worked out why. They discovered the LDL receptor, a molecular docking port on liver cells that grabs LDL particles out of the blood and clears them.[5] People with FH inherit a faulty gene for this receptor, the most common cause of FH, so their livers cannot clear LDL efficiently, and it builds up in the blood from birth.[10][9]

Their Nobel Prize-winning work established the central fact of the field: LDL in the blood drives disease, and how well the body clears LDL determines how much disease develops.[5] It also set the stage for statins, the first drugs able to boost the liver's LDL-clearing machinery.[5]

The family that taught us about PCSK9

The next chapter, decades later, again came from studying families. This time, the key families had unusually low cholesterol. Researchers found that some people carry natural loss-of-function changes in a gene called PCSK9. Normally, PCSK9 acts like a wrecking crew that destroys LDL receptors, leaving fewer of them to clear LDL. People born with a broken PCSK9 gene have more LDL receptors, lower LDL for their entire lives, and remarkably fewer heart attacks.[7][11]

The numbers were astonishing. In one landmark population study, people carrying a PCSK9 variant had LDL that was about 15-28% lower, but their lifetime risk of coronary heart disease was reduced by roughly 47-88%.[12] One woman was found to have essentially no working PCSK9 at all, with an LDL cholesterol of about 14 mg/dL, and she was healthy, fertile, and normal in every other way.[7]

Two lessons emerged that now guide modern prevention:

• Lower is better. There does not appear to be a harmful "too low" threshold at which LDL stops being beneficial to reduce; naturally very low levels are safe.[2]
• Earlier and longer is better. A modest reduction sustained across an entire lifetime protects far more than the same reduction started late. Because these people had low LDL from birth, their protection was much greater than a similar drop achieved by starting a pill in middle age.[12][1]

That discovery led directly to a new class of medicines, PCSK9 inhibitors, designed to copy this fortunate genetic trait in everyone else.[7][11]

Cumulative exposure: the pack-years of cholesterol

The single most important idea in cholesterol science today is cumulative exposure. Arteries age according to the total amount of LDL they are bathed in over the years: LDL level multiplied by time.[1] It behaves much like cigarette pack-years or lifetime sun exposure.

This is why someone with lifelong moderately low LDL is better protected than someone who lowers a high LDL only after age 60, and why the newest guidelines emphasize treating dyslipidemia earlier in life rather than waiting for a crisis.[1][13]

The proof: what the big trials and population studies show

The idea that lowering LDL prevents disease is not a theory. It is one of the most tested claims in medicine, confirmed across hundreds of thousands of people.[1] Three lines of evidence point the same direction, no matter how LDL is lowered:

• Genetics, nature's randomized trial: People born with lower LDL, for any of a dozen different genetic reasons, have less heart disease. This tells us LDL is a cause, not just a bystander.[12][1]
• Population studies: Across large groups followed for years, higher LDL consistently tracks with more heart attacks and strokes.[1]
• Randomized controlled trials: The gold standard, where people are randomly assigned to treatment or placebo, repeatedly shows that lowering LDL lowers the risk of cardiovascular events. Pooled analyses of dozens of trials from the Cholesterol Treatment Trialists' Collaboration found that for roughly every 39 mg/dL, or 1 mmol/L, drop in LDL, major vascular events fall by about a fifth.[14]

What is striking is that this holds true across completely different drugs that lower LDL through completely different mechanisms.

Statins were the first and most studied class. They reduced heart attacks, strokes, and deaths in trials from the 1990s onward, in both people who already had heart disease and those who did not.[15][16]

Ezetimibe, a gut cholesterol blocker, was added to a statin in the IMPROVE-IT trial in patients after a heart attack. Adding it lowered LDL further and cut cardiovascular events further, the first proof that a non-statin added on top of a statin adds benefit.[16]

PCSK9 inhibitors, the drugs born from the family discovery, were tested in the FOURIER trial with evolocumab and the ODYSSEY OUTCOMES trial with alirocumab. On top of a statin, they drove LDL to very low levels and further reduced heart attacks and strokes, with benefit continuing even among people whose LDL fell to extremely low levels.[2][16]

The unifying message is what scientists call the LDL hypothesis, now essentially proven: it is the LDL and apoB particle burden itself that matters, not the particular pill.[1] Many roads lead to the same destination. Clearing that particle, by whatever means, is what protects the artery.[7]

Beyond LDL: non-HDL cholesterol and apoB

Because every atherogenic particle, including LDL and cholesterol-carrying remnants, wraps itself in one apoB protein, the truest measure of danger is the number of apoB particles in the blood, not just the cholesterol carried inside LDL.[17]

Two numbers get closer to that particle count than LDL alone, and both come from a standard lipid panel:

• Non-HDL cholesterol is the simplest. It is total cholesterol minus HDL, or "good" cholesterol, and represents the cholesterol carried by every harmful particle combined. It costs nothing extra, tracks closely with apoB, and predicts risk at least as well as LDL, especially when triglycerides are high. This is the number used to score the cholesterol domain of your Vital8 score, because it captures the full atherogenic burden from an ordinary blood test.[17]
• ApoB is a direct laboratory count of atherogenic particles. It is especially useful when LDL looks reassuring but risk is not, a common mismatch in people with metabolic syndrome, diabetes, or high triglycerides, where LDL can appear at goal while the particle count remains high. For the deeper version, read ApoB Test: What It Measures, Why It Matters, and How to Lower It. In those situations, apoB is the more reliable guide.[17]

If your LDL looks fine but you carry metabolic risk factors, ask your clinician about checking non-HDL cholesterol or apoB.[17]

Where we are going: current targets

Cholesterol is measured with a simple blood test. Treatment is guided both by the percentage LDL is reduced and by the absolute level achieved, tailored to a person's overall risk.[18]

Under the 2026 U.S. dyslipidemia guideline, people who already have heart disease and are at very high risk, meaning secondary prevention, have a goal of LDL below 55 mg/dL. This is a change from the prior 2018 guideline, which used 70 mg/dL as the main benchmark.[19][18]

For those at high risk who have not yet had an event, meaning primary prevention, the goal is LDL below 70 mg/dL. For intermediate risk, the goal is below 100 mg/dL, with the general aim of cutting LDL substantially.[18] People with very high LDL from birth, usually 190 mg/dL or above and often signaling FH, those with diabetes, and those with certain other conditions are generally candidates for treatment regardless of their calculated risk score.[18]

Risk itself is now estimated with a tool called the PREVENT equations, sometimes refined with a coronary artery calcium scan, which looks directly for calcified plaque in the heart's arteries.[18]

Recent research continues to test how low to go. A 2026 trial in people with established heart disease found that targeting LDL under 55 mg/dL further reduced cardiovascular events compared with targeting under 70 mg/dL, without a meaningful increase in side effects, reinforcing the lower-is-better principle.[20]

Why this became a disease of modern life

Heart disease from cholesterol has become common in the modern era for two reasons that pull in the same direction.

First, cardiometabolic syndrome. Modern diets, physical inactivity, and rising rates of obesity have produced an epidemic of what doctors call metabolic, or cardiovascular-kidney-metabolic, syndrome: the cluster of abdominal weight gain, high blood pressure, high blood sugar, and abnormal lipids.[21] This state raises the number of atherogenic apoB particles in the blood, which is the feature that most directly drives plaque.[17]

In people with this metabolic pattern, a standard LDL number can even understate the danger, because the particle count can run high even when LDL looks acceptable. This is one reason doctors increasingly measure apoB or non-HDL cholesterol directly.[17]

Second, we are living much longer. Because atherosclerosis is driven by cumulative lifetime LDL exposure, simply living into our 70s, 80s, and 90s gives plaque more decades to build.[1] A century ago, many people died of other causes before heart disease fully declared itself. Today, longevity is a triumph, but it means LDL has more time to do its damage, making its control over a lifetime more important than ever.

Living longer is only worth it if we live healthier

The goal is not merely more years, but more good years. This is where LDL control shows its value. Because older adults have the highest rates of heart attacks and strokes to begin with, the absolute benefit of lowering LDL can be greatest for them. Each percentage point of risk reduction prevents more real events.[22]

The benefit clearly persists into older age: a meta-analysis of randomized trials found that lowering LDL significantly reduced major vascular events in people over 75, with only a slight and statistically borderline attenuation compared with younger patients.[14] Keeping LDL low is therefore not about squeezing out an extra statistic. It is about arriving at one's later years with arteries, and a brain, intact enough to enjoy them.

LDL is not only about the heart

The same LDL particles that damage the heart's arteries damage arteries elsewhere, and the science increasingly separates where LDL truly causes harm from where it does not.

Peripheral artery disease. Higher LDL is a genuine, causal driver of clogged arteries in the legs, which can cause pain with walking and, in severe cases, threaten the limb. Genetic studies confirm this is cause and effect, not coincidence.[23][2]

Kidney disease. In people with chronic kidney disease, lowering LDL clearly reduces heart attacks, strokes, and other atherosclerotic events, as the SHARP trial showed. Its effect on kidney function itself is less certain: SHARP did not significantly slow progression to kidney failure, and reviews of statin trials find little to no effect on the decline of kidney function. The clear, proven benefit in kidney patients is cardiovascular.[24][25]

Dementia and thinking. This area is frequently misunderstood. Large, high-quality trials of statins, ezetimibe, and PCSK9 inhibitors, including studies in which LDL was driven to extremely low levels, have not shown that lowering LDL harms memory or causes dementia. If anything, well-controlled LDL and cardiovascular health are increasingly viewed as part of protecting the aging brain, since the blood vessels that feed the brain benefit from the same care as those that feed the heart. Occasional reports of brain fog after starting a statin have not held up as a true causal effect in rigorous studies.[2]

By contrast, the tiniest blood vessels of the eye and nerves do not appear to be driven by LDL. That is a useful reminder that LDL is specifically a disease of arteries, large and medium-sized.[23]

A brief guide to lipid-lowering lifestyle

Healthy habits are the foundation for everyone, at every risk level, and for many younger and lower-risk people they are the main treatment.[26][18]

The most effective steps include:

• Eat a heart-protective pattern. Emphasize vegetables, fruits, legumes, nuts, whole grains, and fish. A Mediterranean-style pattern is well supported. For a practical nutrition guide, see Eating Well Without Overthinking It.[26]
• Cut the LDL-raising foods. Reduce saturated fat, and minimize trans fats, processed and red meats, refined carbohydrates, and sugar-sweetened drinks.[26][27]
• Move regularly. Aim for at least 150 minutes per week of moderate activity, or 75 minutes of vigorous activity.[26]
• Avoid all tobacco and nicotine, and manage weight, blood pressure, blood sugar, and sleep. These are the rest of Life's Essential 8, which work together with cholesterol.[26]

A brief guide to lipid-lowering therapy

When lifestyle alone is not enough, or when risk is high enough that waiting is unwise, safe, effective medicines are available and can be layered together to reach the target.[18]

Statins are the first-line, best-proven medicine. They boost the liver's LDL clearance, lower LDL substantially, with high-intensity statins reducing LDL by roughly 50% or more, and have decades of evidence for preventing heart attacks, strokes, and death.[15][14]

Ezetimibe is a well-tolerated pill usually added next, blocking cholesterol absorption in the gut for an additional reduction.[16][18]

PCSK9 inhibitors, including evolocumab and alirocumab, are injectable antibodies that lower LDL by about 50-60% on top of a statin and reduce cardiovascular events. Inclisiran, a related injection given only twice a year, blocks PCSK9 production and lowers LDL by about 50% as well.[28]

Bempedoic acid is an oral option, especially useful for people who cannot tolerate statins; in the CLEAR Outcomes trial it lowered LDL by about 21% and reduced major cardiovascular events by 13%.[29][30]

Most people with inherited high cholesterol need a combination of these to reach goal, and treating earlier in life yields the greatest lifetime benefit.[9][31]

Frequently asked questions

What is a good LDL level? For healthy adults at low risk, lower is generally better, and many experts consider an LDL well under 100 mg/dL desirable. People at high risk aim for under 70 mg/dL, and those with established heart disease at very high risk aim for under 55 mg/dL. Your personal target depends on your overall risk; ask your clinician.[19][18]

What is the difference between LDL and HDL? LDL is the particle that deposits cholesterol in artery walls and drives plaque; it is the bad cholesterol you want low. HDL, or "good" cholesterol, helps carry cholesterol away, and higher levels are associated with lower risk in observational studies. But genetic research shows HDL is not itself a cause of heart disease, and drugs that raise HDL have not reduced events. That is why HDL is no longer a treatment target, and LDL and apoB remain the focus.[32][33]

What is non-HDL cholesterol? It is total cholesterol minus HDL, the cholesterol carried by all the harmful, plaque-forming particles combined. It requires no extra test, and it is the number used to grade the cholesterol part of your Vital8 score.[17]

Can I lower LDL without medication? Often, yes. A heart-healthy diet, regular activity, weight management, and avoiding tobacco can meaningfully lower LDL, and for many lower-risk people this is the primary treatment. People with very high LDL, inherited high cholesterol, or established heart disease usually need medication in addition to lifestyle to reach goal.[26][18]

Is an LDL under 40 too low? No evidence suggests it is harmful. Trials that drove LDL below 20-25 mg/dL found continued cardiovascular benefit without cognitive harm, and people born with genetically very low LDL are healthy.[7][2]

The bottom line: a preventable disease

Cholesterol is one of medicine's great success stories in the making. We understand the biology deeply, we can measure the risk, and we have a toolbox, from diet to statins to PCSK9 inhibitors, that can safely bring LDL to protective, even genetically lucky, levels.[7][18]

Because arterial damage accumulates slowly over decades, acting earlier and keeping LDL low over a lifetime offers the best chance to prevent heart attacks and strokes before they ever happen, and to help people live more healthy, active years.[1]

Related reading

• Vital8 Control Cholesterol
• Life's Essential 8 and the Vital8 framework
• Check your Vital8 score
• Eating Well Without Overthinking It
• The Science Behind Vital8
• Vital8 Methods and Scoring System
• Cholesterol Blood Tests: LDL-C vs ApoB vs Lp(a) vs hs-CRP
• ApoB Test: What It Measures, Why It Matters, and How to Lower It
• Lipoprotein(a): The Inherited Cholesterol Particle Most People Have Never Heard Of

References

1. Reprint Of: Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Journal of the American College of Cardiology. 2018;72(23 Pt B):2980-2995. doi:10.1016/j.jacc.2018.10.021.
2. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke. Goldstein LB, Toth PP, Dearborn-Tomazos JL, et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023;43(10):e404-e442. doi:10.1161/ATV.0000000000000164.
3. Heart Disease and Stroke Statistics-2023 Update. Tsao CW, Aday AW, Almarzooq ZI, et al. Circulation. 2023;147(8):e93-e621. doi:10.1161/CIR.0000000000001123.
4. Global Burden of 292 Causes of Death in 204 Countries and Territories and 660 Subnational Locations, 1990-2023. GBD 2023 Causes of Death Collaborators. Lancet. 2025;406(10513):1811-1872. doi:10.1016/S0140-6736(25)01917-8.
5. Discovery of the Cellular and Molecular Basis of Cholesterol Control. Schekman R. Proceedings of the National Academy of Sciences. 2013;110(37):14833-14836. doi:10.1073/pnas.1312967110.
6. Apolipoprotein B-Containing Lipoproteins in Atherogenesis. Boren J, Packard CJ, Binder CJ. Nature Reviews Cardiology. 2025;22(6):399-413. doi:10.1038/s41569-024-01111-0.
7. The Evolving Future of PCSK9 Inhibitors. Rosenson RS, Hegele RA, Fazio S, Cannon CP. Journal of the American College of Cardiology. 2018;72(3):314-329. doi:10.1016/j.jacc.2018.04.054.
8. The Severe Hypercholesterolemia Phenotype: Clinical Diagnosis, Management, and Emerging Therapies. Sniderman AD, Tsimikas S, Fazio S. Journal of the American College of Cardiology. 2014;63(19):1935-1947. doi:10.1016/j.jacc.2014.01.060.
9. Familial Hypercholesterolemia: JACC Focus Seminar 4/4. Brandts J, Ray KK. Journal of the American College of Cardiology. 2021;78(18):1831-1843. doi:10.1016/j.jacc.2021.09.004.
10. Genetic Testing for Familial Hypercholesterolemia: Past, Present, and Future. Futema M, Taylor-Beadling A, Williams M, Humphries SE. Journal of Lipid Research. 2021;62:100139. doi:10.1016/j.jlr.2021.100139.
11. Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis. Urban D, Poss J, Bohm M, Laufs U. Journal of the American College of Cardiology. 2013;62(16):1401-1408. doi:10.1016/j.jacc.2013.07.056.
12. Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. The New England Journal of Medicine. 2006;354(12):1264-1272. doi:10.1056/NEJMoa054013.
13. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. Stone NJ, Smith SC, Orringer CE, et al. Journal of the American College of Cardiology. 2022;79(8):819-836. doi:10.1016/j.jacc.2021.12.016.
14. Efficacy and Safety of Statin Therapy in Older People: A Meta-Analysis of Individual Participant Data From 28 Randomised Controlled Trials. Cholesterol Treatment Trialists' Collaboration. Lancet. 2019;393(10170):407-415. doi:10.1016/S0140-6736(18)31942-1.
15. Statin Therapy in Primary and Secondary Cardiovascular Disease Prevention. Paparodis RD, Bantouna D, Livadas S, Angelopoulos N. Current Atherosclerosis Reports. 2024;27(1):21. doi:10.1007/s11883-024-01265-9.
16. Systematic Review for the 2018 Blood Cholesterol Guideline. Wilson PWF, Polonsky TS, Miedema MD, et al. Circulation. 2019;139(25):e1144-e1161. doi:10.1161/CIR.0000000000000626.
17. 2026 Guideline on the Management of Dyslipidemia. Writing Committee Members, Blumenthal RS, Morris PB, et al. Circulation. 2026;153(17):e1154-e1276. doi:10.1161/CIR.0000000000001423.
18. 2026 Dyslipidemia Guideline-at-a-Glance. Wiggins BS, Barac A, Benziger CP, et al. Journal of the American College of Cardiology. 2026;87(19):2617-2623. doi:10.1016/j.jacc.2026.02.4872.
19. 2026 Guideline on the Management of Dyslipidemia. Blumenthal RS, Morris PB, Gaudino M, et al. Journal of the American College of Cardiology. 2026;87(19):2624-2757. doi:10.1016/j.jacc.2025.11.016.
20. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease. Lee YJ, Lee SJ, Kim JW, et al. The New England Journal of Medicine. 2026. doi:10.1056/NEJMoa2600283.
21. A Synopsis of the Evidence for Cardiovascular-Kidney-Metabolic Syndrome. Ndumele CE, Neeland IJ, Tuttle KR, et al. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001186.
22. Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older. Orkaby AR, Driver JA, Ho YL, et al. JAMA. 2020;324(1):68-78. doi:10.1001/jama.2020.7848.
23. Impact of LDL Cholesterol on Microvascular Versus Macrovascular Disease. Emanuelsson F, Nordestgaard BG, Tybjaerg-Hansen A, Benn M. Journal of the American College of Cardiology. 2019;74(11):1465-1476. doi:10.1016/j.jacc.2019.07.037.
24. The Effects of Lowering LDL Cholesterol With Simvastatin Plus Ezetimibe in Patients With Chronic Kidney Disease. Baigent C, Landray MJ, Reith C, et al. Lancet. 2011;377(9784):2181-2192. doi:10.1016/S0140-6736(11)60739-3.
25. HMG CoA Reductase Inhibitors for People With Chronic Kidney Disease Not Requiring Dialysis. Tunnicliffe DJ, Palmer SC, Cashmore BA, et al. The Cochrane Database of Systematic Reviews. 2023;11:CD007784. doi:10.1002/14651858.CD007784.pub3.
26. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Arnett DK, Blumenthal RS, Albert MA, et al. Journal of the American College of Cardiology. 2019;74(10):e177-e232. doi:10.1016/j.jacc.2019.03.010.
27. Obesity, Dyslipidemia, and Cardiovascular Disease. Bays HE, Kirkpatrick CF, Maki KC, et al. Journal of Clinical Lipidology. 2024;18(3):e320-e350. doi:10.1016/j.jacl.2024.04.001.
28. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. Wright RS, Ray KK, Raal FJ, et al. Journal of the American College of Cardiology. 2021;77(9):1182-1193. doi:10.1016/j.jacc.2020.12.058.
29. Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs. Lincoff AM, Ray KK, Sasiela WJ, et al. Journal of the American College of Cardiology. 2024;84(2):152-162. doi:10.1016/j.jacc.2024.04.048.
30. Impact of Bempedoic Acid on Total Cardiovascular Events. Nicholls SJ, Nelson AJ, Lincoff AM, et al. JAMA Cardiology. 2024;9(3):245-253. doi:10.1001/jamacardio.2023.5155.
31. Familial Hypercholesterolemia. Stein JH, Tattersall MC. JAMA. 2026. doi:10.1001/jama.2026.8822.
32. Mendelian Randomization. Emdin CA, Khera AV, Kathiresan S. JAMA. 2017;318(19):1925-1926. doi:10.1001/jama.2017.17219.
33. Mendelian Randomization of Blood Lipids for Coronary Heart Disease. Holmes MV, Asselbergs FW, Palmer TM, et al. European Heart Journal. 2015;36(9):539-550. doi:10.1093/eurheartj/eht571.

This guide is part of the MendelMD preventive cardiology library. Explore cholesterol and lipid guides and the LDL reduction calculator. Vital8 is our broader framework for cardiovascular health.